#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4836	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2679	518.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1824	1824	C	664	C,A	545,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8358	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4095	593.8	0	.	n	.	0	T695C	SNP	695	695	T	1323	1323	C	618	C,T,A	524,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8358	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4095	593.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2599	2599	C	682	C,A,T	578,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8358	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4095	593.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2673	2673	A	719	A,C	604,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	8358	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4095	593.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	3225	3225	C	734	C,A,T	600,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	644	folP	855	855	99.88	folP.l15.c4.ctg.1	1946	96.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1692	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3768	130.8	0	.	p	.	0	A92P	NONSYN	274	276	GCA	716	718	CCA	134;134;136	C;C;A	120;117;117	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1692	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3768	130.8	1	SNP	p	S91F	1	.	.	271	273	TTC	713	715	TTC	133;132;134	T;T;C	115;112;118	gyrA.WHO_G_01105:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1692	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3768	130.8	1	SNP	p	D95G	0	.	.	283	285	GAC	725	727	GAC	134;135;135	G;A;C	117;117;114	gyrA.WHO_G_01105:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	1692	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3768	130.8	1	SNP	p	D95N	0	.	.	283	285	GAC	725	727	GAC	134;135;135	G;A;C	117;117;114	gyrA.WHO_G_01105:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	800	mtrR	633	633	100.0	mtrR.l6.c4.ctg.1	1742	134.8	1	SNP	p	G45D	1	.	.	133	135	GAC	692	694	GAC	200;199;199	G;A;C	170;166;169	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	506	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	1350	109.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1586	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3418	135.2	1	SNP	p	D86N	0	.	.	256	258	GAC	792	794	GAC	174;172;172	G;A,C;C	138;134,2;139	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1586	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3418	135.2	1	SNP	p	S87W	0	.	.	259	261	AGT	795	797	AGT	171;170;170	A,C;G;T	125,2;144;142	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1586	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3418	135.2	1	SNP	p	S87R	0	.	.	259	261	AGT	795	797	AGT	171;170;170	A,C;G;T	125,2;144;142	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1586	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3418	135.2	1	SNP	p	S87I	0	.	.	259	261	AGT	795	797	AGT	171;170;170	A,C;G;T	125,2;144;142	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	27	1586	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3418	135.2	1	SNP	p	S88P	0	.	.	262	264	TCC	798	800	TCC	170;168;169	T;C;C	141;140;140	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1390	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3099	130.2	0	.	p	.	0	P456S	NONSYN	1366	1368	CCC	1993	1995	TCC	168;169;168	T;C;C	132;140;142	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1390	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3099	130.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1855	1857	GGC	178;177;177	G;G;C	151;144;138	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	A311V	0	.	.	931	933	GCC	1446	1448	GCC	181;181;181	G,T;C;C	150,1;150;148	penA.27.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	I312M	1	.	.	934	936	ATG	1449	1451	ATG	182;182;183	A;T,G;G,T	156;150,1;151,1	penA.27.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	T316P	0	.	.	946	948	ACC	1461	1463	ACC	182;183;183	A,C;C;C	149,1;148;155	penA.27.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	V316T	1	.	.	946	948	ACC	1461	1463	ACC	182;183;183	A,C;C;C	149,1;148;155	penA.27.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1962	1964	ACC	200;201;201	A;C;C	165;167;166	penA.27.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	A501V	0	.	.	1501	1503	GCG	2016	2018	GCG	195;194;194	G,A;C,G;G	162,1;158,2;155	penA.27.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	A501P	0	.	.	1501	1503	GCG	2016	2018	GCG	195;194;194	G,A;C,G;G	162,1;158,2;155	penA.27.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	G542S	0	.	.	1624	1626	GGT	2139	2141	GGT	183;183;182	G;G;T	157;155;154	penA.27.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	G545S	1	.	.	1633	1635	AGC	2148	2150	AGC	183;181;182	A,C;G,T;C,G	146,1;150,1;151,1	penA.27.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.27.001	penA.27.001	1	1	27	1388	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2758	146.6	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2166	2168	CCG	184;184;185	C;C;G	154;158;159	penA.27.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1740	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3476	145.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1792	1794	CCG	136;136;135	C;C;G,T	110;102;109,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	842	porA	1146	1146	99.65	porA.l6.c17.ctg.1	2172	111.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	537	539	GGC	151;149;148	G;G,C;C,T	129;126,1;125,1	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	842	porA	1146	1146	99.65	porA.l6.c17.ctg.1	2172	111.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	719	719	C	121	C	97	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	887	889	AAG	212;213;212	A,C;A,C;G	172,1;179,1;179	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1163	1165	GAT	168;168;167	G;A;T	141;133;139	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1166	1168	GGT	168;166;166	G,A;G,A;T,A	140,1;134,1;136,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	0	.	p	.	0	V215A	NONSYN	643	645	GTT	1172	1174	GCT	163;163;164	G,T;C,T;T	134,1;135,1;136	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1181	1183	ATG	159;159;161	A,G;T,C;G,C	132,1;127,1;129,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1298	1300	ACG	125;125;126	A,T;C;G,C	107,1;107;108,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1304	1306	GTT	124;123;122	G,T;T,C;T	103,1;106,1;109	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1418	1420	AAC	128;128;128	A;A;C	109;105;106	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	1	SNP	p	A121D	1	.	.	361	363	GAC	890	892	GAC	212;213;213	G;A;C,A	177;175;175,1	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	948	porB1b	1047	1047	98.76	porB1b.l15.c4.ctg.1	1913	141.6	1	SNP	p	D121N	0	.	.	361	363	GAC	890	892	GAC	212;213;213	G;A;C,A	177;175;175,1	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	3200	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5333	175.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2270	2272	CAT	177;177;177	C;A;T	150;148;148	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	546	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1446	109.9	1	SNP	p	V57M	1	.	.	169	171	ATG	667	669	ATG	194;194;194	A,T;T,G;G	162,1;166,1;162	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
